The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Sarcopenia, the age‐related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited. Methods: Here, we assessed the efficacy of espindolol on muscle mass in 19‐month‐old male Wistar Han rats (weight, 555 ± 18 g), including safety issues. Rats were randomized to treatment with 3 mg/kg/day espindolol (n = 8) or placebo (n = 14) for 31 days. Results: Placebo‐treated rats progressively lost body weight (−15.5 ± 7.2 g), lean mass (−1.5 ± 4.2 g), and fat mass (−15.6 ± 2.7 g), while espindolol treatment increased body weight (+8.0 ± 6.1 g, p < 0.05), particularly lean mass (+43.4 ± 3.5 g, p < 0.001), and reduced fat mass further (−38.6 ± 3.4 g, p < 0.001). Anabolic/catabolic signaling was assessed in gastrocnemius muscle. Espindolol decreased proteasome and caspase‐3 proteolytic activities by approximately 50 % (all p < 0.05). Western blotting showed a reduced expression of key catabolic regulators, including NFκB, MuRF1, and LC‐3 (all p < 0.01). The 50‐ and 26‐kDa forms of myostatin were downregulated fivefold and 20‐fold, respectively (both p < 0.001). Moreover, 4E‐BP‐1 was reduced fivefold (p < 0.01), while phospho‐PI3K was upregulated fivefold (p < 0.001), although Akt expression and phosphorylation were lower compared to placebo (all p < 0.05). No regulation of p38 and expression of ERK1/2 were observed, while phosphorylation of p38 was reduced (−54 %, p < 0.001) and ERK1/2 was increased (115 and 83 %, respectively, both p < 0.01). Espindolol did not affect cardiac function (echocardiography) or clinical plasma parameters. Conclusion: Espindolol reversed the effects of aging/sarcopenia, particularly loss of muscle mass and increased fat mass. Thus, espindolol is an attractive candidate drug for the treatment of sarcopenia patients. Electronic supplementary material: The online version of this article (doi:10.1007/s13539‐013‐0125‐7) contains supplementary material.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“Sarcopenia is a condition associated with loss of skeletal muscle mass and strength associated with aging [1].”
BackgroundThe healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Skeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women
Janssen, I. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh058 · Cited by 1,190
Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women
Iannuzzi-Sucich, M., Prestwood, K. M., & Kenny, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.12.m772 · Cited by 890 · cited 1×
“9 %, respectively, in those over 80 years of age [4].”
BackgroundAn overview of sarcopenia: facts and numbers on prevalence and clinical impact
von Haehling, S., Morley, J. E., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0014-2 · Cited by 888 · cited 2×
“Current therapy strategies aim at preventing sarcopenia by exercise regiments, sometimes in combination with nutritional support [11] or the use of hormonal replacement therapy [12].”
BackgroundSelf-citationSarcopenia: origins and clinical relevance
Rosenberg, I. H. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.003 · Cited by 786
Adult lean body mass declines with age: Some longitudinal observations
Forbes, G. B., & Reina, J. C. (1970) · Metabolism · doi:10.1016/0026-0495(70)90062-4 · Cited by 684
Functional consequences of sarcopenia and dynapenia in the elderly
Clark, B. C., & Manini, T. M. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328337819e · Cited by 359 · cited 1×
“Thus, it represents a major economic, social, and public health issue [10], but there are still no treatment options registered, which makes the development of novel medications imperative to reduce the great health and economic burden of sarcopenia.”
BackgroundWhitman, S. A., Wacker, M. J., Richmond, S. R., & Godard, M. P. (2005) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-005-1473-8 · Cited by 156 · cited 1×
“An upregulation of caspase activity and apoptosis was described in old rats [31] and in a single human study, comparing biopsies from young and elderly persons [32].”
Result
Cited by
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
“models, MT-102 has been shown to reverse sarcopenia.(35) Further studies of MT-102 as a treatment of sarcopenia are currently underway.”
BackgroundSarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease
Marty, E., Liu, Y., Samuel, A., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 288
Pharmacologic Options for the Treatment of Sarcopenia
Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225
“It increases muscle mass and decreases fat mass in older animals [156].”
BackgroundSkeletal muscle wasting in chronic heart failure
Suzuki, T., Palus, S., & Springer, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12387 · Cited by 134
Self-citation
Metadata
- Authors
- Pötsch, M. S., Tschirner, A., Palus, S., von Haehling, S., Doehner, W., Beadle, J., Coats, A. J. S., Anker, S. D., & Springer, J.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2013-11-22
- Volume
- 5
- Issue
- 2
- Pages
- 149-158
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2116264302
- Cited by
- 72
- References
- 9
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. https://app.cochat.ai/papers/10.1007/s13539-013-0125-7
- The paper
- Pötsch, M. S., Tschirner, A., Palus, S., von Haehling, S., Doehner, W., Beadle, J., Coats, A. J. S., Anker, S. D., & Springer, J. (2014). The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1007/s13539-013-0125-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.